MedPatent AI (Commercialized.bio)

1. Inspiration:

We saw countless groundbreaking biomedical discoveries languishing in academic journals or patent offices, never making it to market—a phenomenon known as the “valley of death”. Traditional tech‑transfer processes are slow, manual, and often lack the entrepreneurial network to spin innovations into startups. We wanted to bridge that gap using AI, turning untapped research into life‑changing products faster and more efficiently.

2. What it does:

MedPatent AI analyzes biomedical patent data and innovative research outputs to score innovations on commercial readiness, technical feasibility, and clinical impact. It then automatically matches high‑potential assets with the right founders, investors, and accelerators—creating a seamless pipeline from lab bench to startup launch in biotech, MedTech, and digital health.

3. How we built it:

Leveraging the Bolt.new platform, we assembled a serverless backend to ingest patent feeds from Google Patents, USPTO, EPO, and WIPO. We trained NLP models on abstracts and claims to extract key innovation features, then layered on a custom recommendation engine to surface optimal founder/investor matches. The front end was quickly prototyped with Bolt.new’s drag‑and‑drop UI components and iterated in real time based on user testing.

4. Challenges we ran into:

• Data Integration: Patent metadata is messy and siloed across jurisdictions; normalizing it required custom parsers and validation logic.
• Domain Expertise: Translating legal and technical patent language into actionable commercial scores demanded close collaboration with TTO advisors.
• User Adoption: Convincing seasoned tech‑transfer officers to trust AI recommendations meant building transparent “explainability” features.

5. Accomplishments that we’re proud of:

• MVP Complete: A fully functional MedPatent AI platform built in 2 weeks on Bolt.new.
• Pilot Engagement: Onboarded 50+ university tech‑transfer offices (TTOs) across the US, Canada, and Europe for early testing.
• Accelerator Attention: Applied to 2 startup accelerators: Y Combinator and AI LaunchPad in Germany. Preparing our applications to other notable startup accelerators and competitions (Entrepreneurship World Cup, EIT Jumpstarter, EIT Health Innostars Awards, etc)

6. What we learned:

• Iterative Feedback Is Critical: Until now, we have done 9 demos with tech transfer offices (TTOs) and researchers guided our feature set and improved trust in AI outputs.
• Explainability Builds Confidence: Adding “why” and “how” each match was recommended dramatically increased user buy‑in.
• Speed vs. Depth Trade‑Off: Bolt.new’s rapid prototyping allowed us to test breadth of features, but deeper domain-driven enhancements will require targeted engineering sprints.

Throughout the development and initial testing phases of MedPatent AI, we gained several crucial insights. We learned the immense potential of AI to unlock value from previously underutilized data, specifically in the realm of intellectual property. The iterative process of building and refining our AI models highlighted the importance of high-quality, domain-specific training data for achieving accurate and meaningful results. We also learned the critical role of direct user engagement and feedback in shaping a product that truly addresses market needs. The interactions with TTOs provided invaluable perspectives on the practical challenges of technology commercialization and helped us refine our platform's features and user experience. Furthermore, we gained a deeper understanding of the complex interplay between innovation, entrepreneurship, and investment in the biomedical sector, reinforcing our belief that a targeted matchmaking platform like MedPatent AI can significantly streamline this process. Finally, participating in this hackathon and building on the Bolt.new platform underscored the power of rapid prototyping and agile development in bringing complex ideas to fruition quickly.

7. What’s next for MedPatent AI:

• We're now preparing to start a deeptech startup called Commercialized.bio, with the mission to revolutionize the commercialization of scientific innovations, especially in the biotech, biomedical, healthcare, and digital health sectors. So, Commercialized.bio will the startup; and MedPatent AI will the platform.
• Expand Data Sources: Integrate clinical trial, grant, and publication datasets for richer commercialization scoring.
• Launch Closed Beta: Roll out to a select cohort of accelerators and student founder programs for hands‑on matchmaking.
• Refine AI Models: Incorporate user feedback to sharpen our recommendation algorithms and predictive forecasts.
• Scale Partnerships: Formalize agreements with TTOs, accelerators, and VC firms to create a thriving ecosystem around the platform.
• Prepare for Funding Round: Leverage our pilot success to secure seed investment and grow the Commercialized.bio startup.
• Our applications to Y Combinator and AI LaunchPad are part of a broader strategy to secure funding and mentorship that will enable us to scale MedPatent AI globally.
• Ultimately, we envision MedPatent AI becoming the go-to platform for commercializing biomedical and healthcare innovations, fostering a vibrant ecosystem where groundbreaking discoveries are consistently transformed into successful, impactful startups that improve human health worldwide.

Built With

• bolt.new
• express.js
• expressjs-apis:-scrappingdog
• groq
• react
• scrappingdog